Galantamine

Acetylcholinesterase inhibitor CAS# 357-70-0

Galantamine

Catalog No. BCN2868----Order now to get a substantial discount!

Product Name & Size Price Stock
Galantamine: 5mg Please Inquire In Stock
Galantamine: 10mg Please Inquire In Stock
Galantamine: 20mg Please Inquire Please Inquire
Galantamine: 50mg Please Inquire Please Inquire
Galantamine: 100mg Please Inquire Please Inquire
Galantamine: 200mg Please Inquire Please Inquire
Galantamine: 500mg Please Inquire Please Inquire
Galantamine: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Galantamine

Number of papers citing our products

Chemical structure

Galantamine

3D structure

Chemical Properties of Galantamine

Cas No. 357-70-0 SDF Download SDF
PubChem ID 9651 Appearance Powder
Formula C17H21NO3 M.Wt 287.4
Type of Compound Alkaloids Storage Desiccate at -20°C
Synonyms Galantamine
Solubility DMSO : ≥ 59 mg/mL (205.32 mM)
*"≥" means soluble, but saturation unknown.
SMILES CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)O
Standard InChIKey ASUTZQLVASHGKV-JDFRZJQESA-N
Standard InChI InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Galantamine

The bulbs of Lycoris radiata

Biological Activity of Galantamine

Description1. Galantamine is an acetylcholinesterase inhibitor, can reduce brain damage induced by hypoxia-ischemia 2. Galantamine may be a candidate drug for treating relapses of METH-seeking behavior.

Galantamine Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Galantamine Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Galantamine

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.4795 mL 17.3974 mL 34.7947 mL 69.5894 mL 86.9868 mL
5 mM 0.6959 mL 3.4795 mL 6.9589 mL 13.9179 mL 17.3974 mL
10 mM 0.3479 mL 1.7397 mL 3.4795 mL 6.9589 mL 8.6987 mL
50 mM 0.0696 mL 0.3479 mL 0.6959 mL 1.3918 mL 1.7397 mL
100 mM 0.0348 mL 0.174 mL 0.3479 mL 0.6959 mL 0.8699 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Galantamine

Galantamine is a potent inhibitor of acetylcholinesterase (AChE) with IC50 value of 410 nM. [1]
Acetylcholinesterase is a hydrolase. It belongs to carboxylesterase family of enzymes It hydrolyzes the neurotransmitter acetylcholine and has very high catalytic activity. AChE exits in many types of conducting tissue: nerve and muscle, motor and sensory fibers and central and peripheral tissues. AChE located on the post-synaptic membrane. It stops the signal transmission by hydrolyzing ACh. Ach plays an important role in neurotransmission. ACh is released into the synaptic cleft then binds to ACh receptors which located on the post-synaptic membrane. Inhibition the activity of AChE will result in impeded neurotransmission by leading to accumulation of ACh in the synaptic cleft. AChE also is an important target for Alzheimer disease.[1]
Galantamine significantly decreased apoptotic effect induced by thapsigargin at 300 nM in SH-SY5Y cells. Galantamine can more significantly increase cell viability in LDH assays at 10 nM in neuroblastoma cells. Galantamine at 300 nM increase the cell viability treated with Aβ. Galantamine significantly increaseed the expression level of Bcl-2 by 3.1 fold at 300nM in chromaffin cells.[1]
Galantamine can significantly incrase the mRNAs level of IGF2 at 3mg/kg in the mice hippoc ampus. Galantamine also transient decrease the BDNF mRNA levels and increase the FGF2 mRNA levels. Galantamine significantly increased the expression of IGF2 protein levels at 3 mg/kg in the hippocampus of mice.[2]
References:
[1].    Arias E, Ales E, Gabilan NH, Cano-Abad MF, Villarroya M, Garcia AG, Lopez MG: Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004, 46(1):103-114.
[2].    Kita Y, Ago Y, Takano E, Fukada A, Takuma K, Matsuda T: Galantamine increases hippocampal insulin-like growth factor 2 expression via alpha7 nicotinic acetylcholine receptors in mice. Psychopharmacology (Berl), 225(3):543-551.

Featured Products
New Products
 

References on Galantamine

Galantamine reverses scopolamine-induced behavioral alterations in Dugesia tigrina.[Pubmed:24402079]

Invert Neurosci. 2014 Sep;14(2):91-101.

In planaria (Dugesia tigrina), scopolamine, a nonselective muscarinic receptor antagonist, induced distinct behaviors of attenuated motility and C-like hyperactivity. Planarian locomotor velocity (pLMV) displayed a dose-dependent negative correlation with scopolamine concentrations from 0.001 to 1.0 mM, and a further increase in scopolamine concentration to 2.25 mM did not further decrease pLMV. Planarian hyperactivity counts was dose-dependently increased following pretreatment with scopolamine concentrations from 0.001 to 0.5 mM and then decreased for scopolamine concentrations >/= 1 mM. Planarian learning and memory investigated using classical Pavlovian conditioning experiments demonstrated that scopolamine (1 mM) negatively influenced associative learning indicated by a significant decrease in % positive behaviors from 86 % (control) to 14 % (1 mM scopolamine) and similarly altered memory retention, which is indicated by a decrease in % positive behaviors from 69 % (control) to 27 % (1 mM scopolamine). Galantamine demonstrated a complex behavior in planarian motility experiments since co-application of low concentrations of Galantamine (0.001 and 0.01 mM) protected planaria against 1 mM scopolamine-induced motility impairments; however, pLMV was significantly decreased when planaria were tested in the presence of 0.1 mM Galantamine alone. Effects of co-treatment of scopolamine and Galantamine on memory retention in planaria via classical Pavlovian conditioning experiments showed that Galantamine (0.01 mM) partially reversed scopolamine (1 mM)-induced memory deficits in planaria as the % positive behaviors increased from 27 to 63 %. The results demonstrate, for the first time in planaria, scopolamine's effects in causing learning and memory impairments and Galantamine's ability in reversing scopolamine-induced memory impairments.

Galantamine treatment in outpatients with mild Alzheimer's disease.[Pubmed:24461047]

Acta Neurol Scand. 2014 Jun;129(6):382-92.

OBJECTIVE: To assess long-term effectiveness of Galantamine in community-dwelling persons with mild Alzheimer's disease. METHODS: Prospective open-label trial including patients with mild AD (NINCDS-ADRDA criteria) treated with Galantamine for up to 36 months. Outcome parameters included ADAS-cog/11, Bayer-ADL scale (self- and caregivers' ratings), 10-item NPI and CGI-change, safety and tolerability measures. Data are presented based on ITT analyses (LOCF). RESULTS: Seventy-five patients (55% women; mean ADAS-cog 22.3; mean age 70.2 years) were treated with Galantamine for approximately 36 months. About 60% (n=45) received a total daily dose of 24 mg Galantamine at final visit. After 3, 6, and 12 months of treatment, mean improvements in ADAS-cog ranged between 2.2 and 3.0 points (all P<0.05). After 24-month treatment, ADAS-cog returned to baseline value and at 3-year follow-up, patient deteriorated on average by 2.9 points. There was significant improvement on the NPI scale between baseline and 3- to 12-month follow-up (all P<0.05) and at 3-year endpoint, a slight deterioration was noted. Activities of daily living (B-ADL) decreased significantly after 24 months in self-ratings and after 12 months in caregivers' ratings. Fifty-four patients reported at least one AE, most of them occurring during the first 2 years of treatment. Among the most frequently (>10%) reported AEs irrespective of causal relationship to study medication were nausea (17.3%), dizziness (12%), and vomiting (10.7%). CONCLUSION: Galantamine was generally safe and well tolerated during the 3-year observation period. Cognition, behavior, and activities of daily living improved during 12 months treatment. At 3-year follow-up, worsening in all outcomes was measured; however, cognition remained improved compared with an untreated population.

Galantamine prevents long-lasting suppression of excitatory synaptic transmission in CA1 pyramidal neurons of soman-challenged guinea pigs.[Pubmed:25064080]

Neurotoxicology. 2014 Sep;44:270-8.

Galantamine, a drug currently approved for the treatment of Alzheimer's disease, has recently emerged as an effective pretreatment against the acute toxicity and delayed cognitive deficits induced by organophosphorus (OP) nerve agents, including soman. Since cognitive deficits can result from impaired glutamatergic transmission in the hippocampus, the present study was designed to test the hypothesis that hippocampal glutamatergic transmission declines following an acute exposure to soman and that this effect can be prevented by Galantamine. To test this hypothesis, spontaneous excitatory postsynaptic currents (EPSCs) were recorded from CA1 pyramidal neurons in hippocampal slices obtained at 1h, 24h, or 6-9 days after guinea pigs were injected with: (i) 1xLD50 soman (26.3mug/kg, s.c.); (ii) Galantamine (8mg/kg, i.m.) followed 30min later by 1xLD50 soman, (iii) Galantamine (8mg/kg, i.m.), or (iv) saline (0.5ml/kg, i.m.). In soman-injected guinea pigs that were not pretreated with Galantamine, the frequency of EPSCs was significantly lower than that recorded from saline-injected animals. There was no correlation between the severity of soman-induced acute toxicity and the magnitude of soman-induced reduction of EPSC frequency. Pretreatment with Galantamine prevented the reduction of EPSC frequency observed at 6-9 days after the soman challenge. Prevention of soman-induced long-lasting reduction of hippocampal glutamatergic synaptic transmission may be an important determinant of the ability of Galantamine to counter cognitive deficits that develop long after an acute exposure to the nerve agent.

Galantamine attenuates reinstatement of cue-induced methamphetamine-seeking behavior in mice.[Pubmed:22260318]

Addict Biol. 2014 Jan;19(1):1-4.

Methamphetamine (METH) dependence is becoming a serious socioeconomic health problem worldwide. The enhancement of the cholinergic nervous system is expected to greatly alleviate drug dependence. We investigated the effect of Galantamine on the reinstatement of cue-induced METH-seeking behavior using a self-administration experiment. Treatment with Galantamine (1 mg/kg, p.o.) 30 minutes before exposure to the cues suppressed the reinstatement of METH-seeking behavior. However, Galantamine did not affect the cue-induced reinstatement of food-seeking behavior or locomotor activity. These results suggest that Galantamine may be a candidate drug for treating relapses of METH-seeking behavior.

Galantamine, an acetylcholinesterase inhibitor, reduces brain damage induced by hypoxia-ischemia in newborn rats.[Pubmed:24972037]

Int J Dev Neurosci. 2014 Oct;37:52-7.

AIM: Our aim is to elucidate whether Galantamine, known as an acetylcholinesterase inhibitor, reduces brain damage induced by hypoxia-ischemia (HI). STUDY DESIGN: 7-day-old Wistar rats were used. Rats were subjected to left carotid artery ligation followed by 2 h of hypoxia (8% oxygen). We injected Galantamine intraperitoneally just before hypoxia (5.0 mg/kg, n=14; 2.5 mg/kg, n=9; 1.0mg/kg, n=11) and after hypoxia (5.0mg/kg, n=7) to determine its neuroprotective effect. An equivalent volume of saline was administered as a control before (n=31) and after hypoxic load (n=7). We also examined the production of IL-1beta in the ligated hemisphere side after injection of Galantamine (prior hypoxia; 5.0 mg/kg, n=7) or saline (n=8). Brains were analyzed 7 days after HI. RESULTS: Two of the 5.0 mg/kg Galantamine pre-treated rats and a post-treated rat died during experiments. The remaining survived and 5.0mg/kg Galantamine pre-treated rats showed a marked reduction of brain damage (p<0.01) compared with the control. The other Galantamine groups had severe brain damage similar to controls. Microglial accumulation was significantly reduced in rats pre-treated with 5.0 mg/kg of Galantamine compared to control rats on both the hippocampus (p=0.02) and cortex (p<0.01). In contrast, the other Galantamine groups showed a lower suppressive effect on microglial accumulation compared to the control. Galantamine significantly reduced IL-1beta productions when compared to the control (p<0.01). CONCLUSION: Pre-treatment of Galantamine reduced brain damage with a suppressive effect on microglial accumulation and IL-1beta production in a newborn rat model of HI.

Description

Galanthamine is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 500 nM.

Keywords:

Galantamine,357-70-0,Galantamine,Natural Products,AChR, buy Galantamine , Galantamine supplier , purchase Galantamine , Galantamine cost , Galantamine manufacturer , order Galantamine , high purity Galantamine

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: